title: Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry.
abstract: A primary objective of pharmacokinetic-pharmacodynamic (PKPD) reasoning is to identify key in vivo drug and system proper¬ties, enabling prediction of the magnitude and time course of drug responses under physiological and pathological conditions in animals and man. Since the pharmacological response generated by a drug is highly dependent on the actual system used to study its action, knowledge about its potency and efficacy at a given concentration or dose is insufficient to obtain a proper understanding of its pharmacodynamic profile. Hence, the output of PKPD activities extends beyond the provision of quantitative measures (models) of results, to the design of future protocols. Furthermore, because PKPD integrates DMPK (e.g. clearance) and pharmacology (e.g. potency),it provides an anchor point for compound selection, and, as such, should be viewed as an important weapon in medicinal chemistry. Here we outline key PK concepts relevant to PD, and then consider real-life experiments to illustrate the importance to the medicinal chemist of data obtained by PKPD. Useful assumptions and potential pitfalls are described, providing a holistic view of the plethora of determinants behind in vitro-in vivo correlations. By condensing complexity to simplicity, there are not only consequences for experimental design, and for the ranking and design of compounds, but it is also possible to make important predictions such as the impact of changes in drug potency and kinetics. In short, by using quantitative methods to tease apart pharmacodynamic complexities such as temporal differences and changes in plasma protein binding, it is possible to target the changes necessary for improving a compound's profile.
authors.affiliation: Discovery DMPK & BAC, Lead Generation and Medicinal Chemistry, AstraZeneca R&D Mölndal, S-43183 Mölndal, Sweden. Johan.Gabrielsson@astrazeneca.com
authors.forename: Johan
authors.initials: J
authors.lastname: Gabrielsson
authors.forename: Ola
authors.initials: O
authors.lastname: Fjellström
authors.forename: Johan
authors.initials: J
authors.lastname: Ulander
authors.forename: Michael
authors.initials: M
authors.lastname: Rowley
authors.forename: Piet H
authors.initials: PH
authors.lastname: Van Der Graaf
mesh_terms: D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D006801:Humans; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D010599:Pharmacokinetics
chemical_list: D004364:Pharmaceutical Preparations